The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI

Personalized cancer vaccines from Moderna and Merck have added more than $50 billion in combined market value for the two drugmakers. That momentum is opening a less obvious investing lane in the diagnostics work behind every dose.

The vaccines depend on genetic sequencing to identify the mutations each patient's immune system should target. That step may be emerging as its own investable opportunity, separate from the vaccines themselves.

A Recurring Business, Not a One-Time Sale

Every personalized cancer vaccine requires a tumor to be sequenced first. Analysts view that step as a recurring, per-patient revenue stream. It is not a one-time service tied to a single drug launch.

One of the diagnostics companies positioned to benefit is Tempus AI, a genomic-sequencing firm. Tempus has said it will serve as the sequencing partner if the Moderna-Merck vaccine wins regulatory approval.

Moderna's own shares have also benefited from investor enthusiasm for its wider drug pipeline, part of a pipeline-driven stock rally that predates the vaccine news.

… Continue reading the full article at the original source below.